Sermonix Pharmaceuticals Overview

  • Founded
  • 2014
Founded
  • Status
  • Private
  • Employees
  • 6
Employees
  • Latest Deal Type
  • Series A3
  • Latest Deal Amount
  • $40M
Latest Deal Amount
  • Investors
  • 5

Sermonix Pharmaceuticals General Information

Description

Developer of pharmaceutical drugs designed to treat breast cancer. The company's drugs are used for women's health, menopause, and selective estrogen receptor modulators, enabling cancer patients to get quality oncology products through proof of concept, clinical development, and regulatory approval.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Pharmaceuticals
Primary Office
  • 3000 East Main Street
  • Suite 218
  • Columbus, OH 43209
  • United States
+1 (614) 000-0000

Sermonix Pharmaceuticals Timeline

2018201920202021
Financing RoundCaptured Employee CountEstimated Employee Growth
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Sermonix Pharmaceuticals Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
4. Later Stage VC (Series A3) 15-Nov-2021 $40M 000.00 00000 Completed Generating Revenue
3. Later Stage VC (Series A1) 31-Jul-2019 0000 000.00 0000 Completed Clinical Trials - Phase 2
2. Seed Round 28-Nov-2017 $4.2M $7.9M Completed Clinical Trials - Phase 2
1. Seed Round 10-Nov-2016 $3.7M $3.7M Completed Clinical Trials - Phase 2
To view Sermonix Pharmaceuticals’s complete valuation and funding history, request access »

Sermonix Pharmaceuticals Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series A3 0,000,000 00.000000 00 000.00 000.00 00 000.00 00.000
Series A-2 000,000 00.000000 00
Series A-1 1,998,257 $0.000100 5% $13.38 $13.38 1x $13.38 35.92%
To view Sermonix Pharmaceuticals’s complete cap table history, request access »

Sermonix Pharmaceuticals Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Developer of pharmaceutical drugs designed to treat breast cancer. The company's drugs are used for women's health, meno
Drug Discovery
Columbus, OH
6 As of 2017
000.00
0000 0000-00-00
00000000000 000.00

00000000

ididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco
0000 000000000
San Diego, CA
00 As of 0000
00000
000000000 00000

00000000

ehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cu
000000000000000
South San Francisco, CA
00 As of 0000
00000
0000000000.
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Sermonix Pharmaceuticals Competitors (69)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Crinetics Pharmaceuticals Formerly VC-backed San Diego, CA 00 00000 000000000 00000
00000000 Formerly VC-backed South San Francisco, CA 00 00000 0000000000.
000 000000000000 Formerly VC-backed Epalinges, Switzerland 000 00.000 00000000 00.000
0000000 0000000000 Venture Capital-Backed Cambridge, United Kingdom 00 00000 00000000000 00000
0 00000 000000 Angel-Backed Houston, TX 000 0000000000 000
You’re viewing 5 of 69 competitors. Get the full list »

Sermonix Pharmaceuticals Patents

Sermonix Pharmaceuticals Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20190231743-A1 Lasofoxifene treatment of vva and osteoporosis in survivors of breast cancer and other malignancies Pending 11-Oct-2016 000000000

Sermonix Pharmaceuticals Executive Team (5)

Name Title Board Seat Contact Info
David Portman MD Founder, Chief Executive Officer, Chief Medical Officer and Board Member
Lawrence Hoffman Chief Financial Officer
Miriam Portman MD Chief Operating Officer & Board Member
Elizabeth Attias Chief Strategy & Development Officer
Barry Komm Ph.D Chief Scientific Officer
To view Sermonix Pharmaceuticals’s complete executive team members history, request access »

Sermonix Pharmaceuticals Board Members (11)

Name Representing Role Since
Anthony Wild Ph.D Sermonix Pharmaceuticals Non-Executive Chairman of the Board 000 0000
Ben Askew Ph.D Sermonix Pharmaceuticals Board Member 000 0000
David Portman MD Sermonix Pharmaceuticals Founder, Chief Executive Officer, Chief Medical Officer and Board Member 000 0000
Elizabeth Garner Self Board Member 000 0000
Frederick Callori Sermonix Pharmaceuticals Board Member 000 0000
You’re viewing 5 of 11 board members. Get the full list »

Sermonix Pharmaceuticals Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Sermonix Pharmaceuticals Investors (5)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Xontogeny Accelerator/Incubator Minority 000 0000 000000 0
Lodewijk de Vink Angel (individual) Minority 000 0000 000000 0
Wild Family Office Family Office Minority 000 0000 000000 0
Richard De Schutter Angel (individual) Minority 000 0000 000000 0
Anthony Wild Angel (individual) Minority 000 0000 000000 0
To view Sermonix Pharmaceuticals’s complete investors history, request access »